Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro

Blood

Volumn 117, Issue 1, 2011, Pages 290-298

  Bunce, Matthew W ^a   Toso, Raffaella ^a   Camire, Rodney M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; ENZYME PRECURSOR; MUTANT PROTEIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; HEMOPHILIA; HEMOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN VARIANT; THROMBOCYTE ACTIVATION;

EID: 78650988916     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-300756     Document Type: Article

References (52)

1. Mann KG, Nesheim ME, Church WR, Haley PE, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76(1):1-16. (Pubitemid 20220784)
2. Bode W, Mayr I, Bauman Y, et al. The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Trp insertion segment. EMBO J. 1989;8(11):3467-3475. (Pubitemid 19273577)
3. Khan AM, James MNG. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Prot Sci. 1998;7(4):815-836.
4. Huber R, Bode W. Structural basis of the activation and action of trypsin. Acc Chem Res. 1978;11114-11122.
5. Camire RM. Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site. J Biol Chem. 2002;277(40):37863-37870.
6. Toso R, Zhu H, Camire RM. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J Biol Chem. 2008;283(27):18627-18635.
7. Foster WB, Nesheim ME, Mann KG. The factor Xa-catalyzed activation of factor V. J Biol Chem. 1983;258(22):13970-13977.
8. Eaton D, Rodriguez H, Vehar G. Proteolytic processing of human FVIII. Correlation of specific cleavages by thrombin FXa and activated protein C with activation and inactivation of Factor VIII coagulant activity. Biochemistry. 1986;25(2):505-512.
9. Butenas S, Mann KG. Kinetics of human factor VII activation. Biochemistry. 1996;35(6):1904-1910.
10. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008;14(10):429-440.
11. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995;46103-46112.
12. Bjork I, Olson ST. Antithrombin. A bloody important serpin. Adv Exp Med Biol. 1997;42517-42533.
13. Roberts HR, Ma AD. Overview of inherited hemorrhagic disorders. In: Colman RW, Marder VJ, Clowes AW, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams and Wilkins; 2006:877-885.
14. Kessler CM, Mariani G. Clinical manifestations and therapy of the hemophilias. In: Colman RW, Marder VJ, Clowes AW, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams and Wilkins; 2006:887-904.
15. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006;124(4):747-757.
16. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
17. Hedner U, Lee CA. First 20 years with recombinant FVIIa (NovoSeven) [published online ahead of print June 29, 2010]. Haemophilia. doi:10.1111/j.1365-2516.2010.02352.x.
18. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3-10.
19. Gitel SN, Medina VM, Wessler S. Inhibition of human activated Factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma. J Biol Chem. 1984;259(11):6890-6895.
20. Jesty J. Analysis of the generation and inhibition of activated coagulation factor X in pure systems and in human plasma. J Biol Chem. 1986;261(19):8695-8702.
21. Giles AR, Nesheim ME, Mann KG. Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. J Clin Invest. 1984;74(6):2219-2225.
22. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988;69(4):491-497.
23. Lottenberg R, Jackson CM. Solution composition dependent variation in extinction coefficients for ρ-nitroaniline. Biochim Biophys Acta. 1983;742(3):558-564.
24. Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem. 1983;258(10):6503- 6508. (Pubitemid 13106824)
25. Buddai SK, Toulokhonova L, Bergum PW, Vlasuk GP, Krishnaswamy S. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem. 2002;277(29):26689-26698.
26. Katzmann JA, Nesheim ME, Hibbard LS, Mann KG. Isolation of functional human coagulation Factor V by using a hybridoma antibody. Proc Natl Acad Sci U S A. 1981;78(1):162-166.
27. Kisiel W, Hermodson MA, Davie EW. Factor X activating enzyme from Russell's Viper Venom: Isolation and characterization. Biochemistry. 1976;15(22):4901-4906.
28. Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem. 2004;279(20):21643-21650.
29. Gowda DC, Jackson CM, Davidson EA. Factor X-activating glycoprotein of Russell's viper venom. Polypeptide composition and characterization of the carbohydrate moieties. J Biol Chem. 1994;269(14):10644-10650.
30. Mann KG. Prothrombin. Methods Enzymol. 1976;45:123-156.
31. Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol. 1976;45:156-176.
32. Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas Factor), factor X (Stuart Factor), and protein S. Biochemistry. 1977;16(4):698-706.
33. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. In: Lorand L, Mann KG, eds. Methods in Enzymology Part A. San Diego, CA: Academic Press; 1993:525-559.
34. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem. 1989;182(2):319-326. (Pubitemid 19277112)
35. Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-derived factor Va/VaLeiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood. 1998;91(8):2818-2829.
36. Hemker HC, Giesen P, Al DR, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15.
37. Straume M, Johnson ML. Analysis of residuals: criteria for determining goodness-of-fit. Methods Enzymol. 1992;210:87-105.
38. Segal IH. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. New York, NY: John Wiley & Sons; 1975.
39. Rezaie AR. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. J Biol Chem. 1998;273(27):16824- 16827.
40. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem. 1998;273(8):4378-4386.
41. Ellis V, Scully MF, Kakkar VV. Inhibition of prothrombinase complex by plasma proteinase inhibitors. Biochemistry. 1984;23(24):5582-5587.
42. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood. 2001;97(8):2308- 2313.
43. Cawthern KM, van't Veer C, Lock JB, et al. Blood coagulation in hemophilia A and hemophilia C. Blood. 1998;91(12):4581-4592.
44. Louvain-Quintard VB, Bianchini EP, Calmel-Tareau C, Tagzirt M, Le Bonniec BF. Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas. J Biol Chem. 2005;280(50):41352-41359.
45. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22(9):1381-1389.
46. Tranholm M, Kristensen K, Kristensen AT, et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102(10):3615-3620.
47. Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat Biotechnol. 2000;18(3):289-295.
48. Wolf DL, Lin PH, Hollenbach S et al. Procoagulant activity of reversibly acylated human factor Xa. Blood. 1995;86(11):4153-4157.
49. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost. 2001;86(1):8-13.
50. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99(3):542-547.
51. van 't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95(4):1330-1335.
52. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99(3):923-930. (Pubitemid 34525554)